EPAX’S Omega-3 Oils Get Australian Approval
There is now a substantial body of scientific evidence supporting the use of the omega-3 fatty acids EPA and DHA for cardiovascular health, joint health, mood health and brain health.
31/08/06 EPAX AS, a world leading supplier of omega-3 concentrates, announced today that after 18 months of working closely with its Australian distributor Pathway International, the company has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA). This approval allows EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia.
The approval comes at a time of increasing consumer awareness of the health benefits of the omega-3 fatty acids EPA and DHA. There is now a substantial body of scientific evidence supporting the use of the omega-3 fatty acids EPA and DHA for cardiovascular health, joint health, mood health and brain health.
“The demand for omega-3 fatty acids is continuing to grow on a global basis,” said Bjorn Refsum, CEO of EPAX AS, “We are pleased customers in Australia will now have access to products from EPAX, as the company is known as one of the world’s leading suppliers of omega-3 concentrates.”
